To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
ATP10B Knockout LS513 Cell Line
Immortalized Cell
LS513 cell line with homozygous knockout of APT10B.
VPS13C Knockout HeLa Cell Line
Immortalized Cell
HeLa cell with homozygous knockout of VPS13C.
USP30 Knockout A549 Cell Line
Immortalized Cell
A549 cell with homozygous knockout of USP30.
GALC Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in GALC, including heterozygous and homozygous R101X, heterozygous and homozygous Y541S, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
NOD2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in NOD2, including heterozygous and homozygous knockout, heterozygous, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
GPNMB Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in GPNMB, including knockout heterozygous and homozygous, heterozygous, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
SCARB2 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SCARB2, including heterozygous and homozygous R424, heterozygous and homozygous W146Sfs*15, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
SMPD1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in SMPD1, including heterozygous and homozygous L262Rfs*3, heterozygous and homozygous Q294K, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
VPS13C Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in VPS13C, including heterozygous and homozygous G1389R, heterozygous and homozygous R117*, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
PSMF1 Edited iPSC Lines
Human iPS Cell
KOLF2.1J human iPSC line with CRISPR-engineered mutations in PSMF1, including heterozygous and homozygous R242C and R231*, and homozygous knockout mutations. These lines were generated within the iPSC Neurodegeneration Initiative for Parkinson’s Disease (iNDI-PD) which is supported by Aligning Science Across Parkinson's (ASAP). Estimated Availability: Q1 2026.
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic